TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ADXN

Addex Therapeutics Ltd - American Depositary Shares

NASDAQ
$3.40
▲ $0.51 (+17.6%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 19 Nov 2026
H $7.27L $2.56-50.1%
$7.27$6.33$5.39$4.44$3.5$2.56$3.4
RSI (14)
Intraday · 15-minSell-20RSI 53DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Buy+35
RSI (14)51
oversold 30overbought 70
Trend
Uptrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
above
vs 200-day
below
Support
$2.68
Resistance
$6.50
  • Price is above its 50-day average (medium-term uptrend).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest · 2026-02-19 → 2026-11-19

Strategy return
-31.6%
Buy & hold
-54.1%
Trades
7
Win rate
0%

$100,000.00 invested would be worth $68,444.16 (-31.6%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Addex Therapeutics Ltd· Biotechnology

source: yahoo

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Sector
Healthcare
Industry
Biotechnology
Employees
3
Headquarters
Geneva, Switzerland
www.addextherapeutics.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:— Neutral0↑ · 0↓ · 8–
  • Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties— Neutral
    BioPharma Dive · 13 Nov 2026
  • Top Midday Gainers— Neutral
    MT Newswires · 12 Nov 2026
  • Addex Therapeutics Spin-Out Neurosterix Closes $105 Million Financing— Neutral
    MT Newswires · 11 Nov 2026
  • Addex Spin-out Neurosterix Closes $105 Million Series B Financing
— Neutral
GlobeNewswire · 11 Nov 2026
  • ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES— Neutral
    GlobeNewswire · 29 Oct 2026
  • Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia— Neutral
    GlobeNewswire · 08 Oct 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.